• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.

作者信息

Jayol Aurélie, Nordmann Patrice, Poirel Laurent, Dubois Véronique

机构信息

Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland.

INSERM European Unit (LEA-IAME Paris, France), University of Fribourg, Fribourg, Switzerland.

出版信息

J Antimicrob Chemother. 2018 Feb 1;73(2):542-544. doi: 10.1093/jac/dkx393.

DOI:10.1093/jac/dkx393
PMID:29165563
Abstract
摘要

相似文献

1
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.单独使用头孢他啶/阿维巴坦或与氨曲南联合使用治疗对黏菌素耐药且产碳青霉烯酶的肺炎克雷伯菌。
J Antimicrob Chemother. 2018 Feb 1;73(2):542-544. doi: 10.1093/jac/dkx393.
2
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
3
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues.在对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌中表达的KPC-31与相关检测问题有关。
J Antimicrob Chemother. 2019 Aug 1;74(8):2464-2466. doi: 10.1093/jac/dkz156.
4
Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.评估产碳青霉烯酶肠杆菌科细菌中头孢他啶/阿维巴坦和氨曲南的体外活性：定义希望区域。
Int J Antimicrob Agents. 2018 Nov;52(5):688-691. doi: 10.1016/j.ijantimicag.2018.07.011. Epub 2018 Jul 22.
5
New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae.多黏菌素或头孢他啶/阿维巴坦耐药肺炎克雷伯菌引起的血流感染的新选择。
Int J Antimicrob Agents. 2021 Dec;58(6):106458. doi: 10.1016/j.ijantimicag.2021.106458. Epub 2021 Oct 25.
6
Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant .头孢他啶-阿维巴坦联合不同抗菌药物对碳青霉烯类耐药. 的影响。
Microbiol Spectr. 2024 Jun 4;12(6):e0010724. doi: 10.1128/spectrum.00107-24. Epub 2024 May 7.
7
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.鉴定头孢他啶-阿维巴坦和亚胺培南-雷利巴坦对碳青霉烯类耐药肠杆菌科的活性谱和治疗窗。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00642-17. Print 2017 Sep.
8
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.头孢他啶-阿维巴坦对一组碳青霉烯类耐药肠杆菌科挑战株的活性：OmpK36 L3 改变和具有头孢他啶水解活性的β-内酰胺酶导致 MIC 值升高。
Int J Antimicrob Agents. 2020 Jul;56(1):106011. doi: 10.1016/j.ijantimicag.2020.106011. Epub 2020 May 15.
9
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
10
Discordance with Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.与活性的不一致：在小鼠肺部感染模型中，头孢他啶-阿维巴坦、氨曲南和替加环素单独及联合使用对产新德里金属β-内酰胺酶的肺炎克雷伯菌的人源化暴露情况。
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00486-17. Print 2017 Jul.

引用本文的文献

1
Combatting mobile colistin-resistant (MCR), metallo-β-lactamase (MBL)-producing persisters.对抗耐黏菌素移动性（MCR）、产金属β-内酰胺酶（MBL）的持留菌。
JAC Antimicrob Resist. 2025 Jul 22;7(4):dlaf132. doi: 10.1093/jacamr/dlaf132. eCollection 2025 Aug.
2
Molecular epidemiology and clinical characteristics of carbapenem-resistant bloodstream and pneumonia isolates.耐碳青霉烯类血流感染和肺炎分离株的分子流行病学及临床特征
Microbiol Spectr. 2025 Aug 5;13(8):e0063125. doi: 10.1128/spectrum.00631-25. Epub 2025 Jul 9.
3
Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant (CRE) of Various Carbapenemase Phenotypes in Southwestern China.
氨曲南作为头孢他啶/阿维巴坦对中国西南部多种碳青霉烯酶表型的耐碳青霉烯肠杆菌科细菌（CRE）的增效剂。
Infect Drug Resist. 2025 May 3;18:2243-2253. doi: 10.2147/IDR.S523498. eCollection 2025.
4
Targeted 'knock out' therapy with a combination antimicrobial regimen restores treatment options in the management of extensively drug-resistant carbapenemase-producing organisms.采用联合抗菌方案的靶向“敲除”疗法为广泛耐药的产碳青霉烯酶微生物的管理恢复了治疗选择。
J Med Microbiol. 2025 Apr;74(4). doi: 10.1099/jmm.0.002007.
5
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.波兰一家单中心对 23 例产新德里金属β-内酰胺酶（NDM）肺炎克雷伯菌感染患者使用头孢他啶/阿维巴坦和氨曲南治疗的结果。
Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.
6
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and .新型β-内酰胺/β-内酰胺酶抑制剂对耐碳青霉烯类肠杆菌科细菌感染的抗菌及诊断管理
Antibiotics (Basel). 2024 Mar 21;13(3):285. doi: 10.3390/antibiotics13030285.
7
Activities of aztreonam in combination with several novel β-lactam-β-lactamase inhibitor combinations against carbapenem-resistant strains coproducing KPC and NDM.氨曲南与几种新型β-内酰胺-β-内酰胺酶抑制剂联合使用对产KPC和NDM的耐碳青霉烯菌株的活性。
Front Microbiol. 2024 Mar 5;15:1210313. doi: 10.3389/fmicb.2024.1210313. eCollection 2024.
8
Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant Treated with Ceftazidime-Avibactam: A Retrospective Study.用头孢他啶-阿维巴坦治疗的耐碳青霉烯类重症患者的临床结局及死亡危险因素：一项回顾性研究
Infect Drug Resist. 2024 Jan 25;17:239-248. doi: 10.2147/IDR.S445243. eCollection 2024.
9
Clinical Characteristics, Drug Resistance, and Risk Factors for Death of Infection in Patients with Acute Pancreatitis: A Single-Center Retrospective Study from China.急性胰腺炎患者感染的临床特征、耐药性及死亡危险因素：一项来自中国的单中心回顾性研究
Infect Drug Resist. 2023 Aug 7;16:5039-5053. doi: 10.2147/IDR.S410397. eCollection 2023.
10
Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study.探索英格兰感染病顾问对一种新型抗菌药物脱钩资助模式的看法：SMASH研究
JAC Antimicrob Resist. 2023 Aug 1;5(4):dlad091. doi: 10.1093/jacamr/dlad091. eCollection 2023 Aug.